DARPP-32 Polyclonal Antibody

Dopamine and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32) is a member of the protein phosphatase inhibitor 1 family and is encoded by the PPP1R1B gene in humans.¹ It is primarily expressed in medium spiny neurons of dopamine-innervated brain regions and is localized to the cytoplasm.² DARPP-32 contains multiple phosphorylation sites that allow it to function as a central regulator and integrator of signaling cascades induced by a variety of neurotransmitters, neuropeptides, and psychostimulatory agents. It also contains a protein phosphatase 1 (PP1) binding domain.³ DARPP-32 inhibits PP1 when phosphorylated at threonine 34 (Thr³⁴) by PKA and inhibits PKA when phosphorylated at Thr⁷⁵ by cyclin-dependent kinase 5 (Cdk5). Ppp1r1b^-/- mice have decreased amphetamine-induced GABA and dopamine release in the striatum and are less susceptible to catalepsy induced by raclopride (Item No. 17422) compared to wild-type mice.⁴ Increased DARPP-32 protein levels have been identified in breast, prostate, gastric, and colon cancer tumors.⁵ DARPP-32 levels are also increased in postmortem-derived dorsolateral prefrontal cortex from individuals with schizophrenia or bipolar disorder.⁶ Cayman's DARPP-32 Polyclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes DARPP-32 at ^~32 kDa from mouse and rat samples.

WARNING This product is not for human or veterinary use.

1.  .

2.  .

3.  .

4.  .

5.  .

6.  .